BACKGROUND: Cardio-embolic etiology is the most frequently predicted cause of cryptogenic @entity64 / @entity4905 . Detection of occult paroxysmal @entity955 is crucial for selection of appropriate medication. METHODS: Enrolment of eligible cryptogenic @entity64 and @entity4905 @entity1 began in 2014 and will continue until 2018. The @entity1 undergo long-term (12  months) ECG monitoring (implantable loop recorder) and testing for @entity20195 (chromosome 4q25) and @entity17553 (chromosome 16q22) gene mutations. There will be an appropriate control group of age- and sex-matched healthy volunteers. To analyse the results descriptive statistics, statistical tests for group differences, and correlation analyses will be used. DISCUSSION: In our study we are focusing on a possible correlation between detection of @entity955 by an implantable ECG recorder, and @entity20195 and/or @entity17553 gene mutations in cryptogenic @entity64 / @entity4905 @entity1 . A correlation could lead to implementation of this genomic approach to cryptogenic @entity64 / @entity4905 diagnostics and management. The results will be published in 2018. TRIAL REGISTRATION: ClinicalTrials.gov: NCT02216370 .

Detection of occult paroxysmal atrial fibrilation by implantable long-term electrocardiographic monitoring in cryptogenic XXXX and transient ischemic attack population: a study protocol for prospective matched cohort study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity20195 :: ('5308', 'Gene') :: ['PITX2'] @entity4905 :: ('MESH:D002546', 'Disease') :: ['TIA'] @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation'] @entity17553 :: ('463', 'Gene') :: ['ZFHX3']
@entity64 :: (MESH:D020521,Disease) :: ['stroke']
